SIU 2017: Second Look Transurethral Resection of Bladder Tumor: Is It Necessary in All T1 and/or High Grade Tumors?
Lisbon, Portugal (UroToday.com) Repeat TURBT after an initial diagnosis of NMIBC, specifically high-grade T1 disease, is recommended by most guidelines. Due to moderate ~20-30% rate of understaging on initial TURBT, repeat TURBT is recommended to ensure that MIBC is not missed. However, considering the potential cost implications, patient discomfort, and potential risks of repeat TURBT, there has been renewed interest to reassess the need of repeat TURBT.
SIU 2017: Lateral Bladder Neck Dissection Technique and Triple-Layer Posterior Bladder Wall Reconstruction Lead to Early Removal of Foley Catheter and Improved Urinary Continence after Robotic-Assisted Radical Prostatectomy
Lisbon, Portugal (UroToday.com) Recovery of urinary continence is an important functional outcome following prostatectomy, including robotic prostatectomy. Various techniques have been attempted to help improve return of urinary continence, including intra-operative vas deferens sling, rocco stitch, etc. Very little has been shown to improve continence except urethral length and sparing of the levator muscles.
SIU 2017: Discerning Predictors for Gender Differences in Survival Outcomes for Patients Treated for Bladder Cancer
Lisbon, Portugal (UroToday.com) Radical cystectomy (RC) is an underutilized treatment option for those with refractory non-muscle invasive and muscle-invasive bladder cancer; however, use of RC may differ according to gender. The authors wanted to discern receipt and timing of RC as well as survival outcomes according to gender.
SIU 2017: Use of Concurrent Chemotherapy with Radiation Therapy for Bladder Cancer in the United States: A Quality of Care Comparative Effectiveness Study
Lisbon, Portugal (UroToday.com) For older bladder cancer patients, there is limited evidence of the efficacy of concurrent chemotherapy with radiation therapy in the community setting. The authors attempted to assess the relationship between concurrent chemotherapy use and survival in a large, population-based cohort of older patients with muscle-invasive bladder cancer.
SIU 2017: Identification of Factors Associated with Delayed Haematuria Assessment
Lisbon, Portugal (UroToday.com) While most causes of hematuria are benign or idiopathic, hematuria is the commonest presenting symptom of bladder cancer. A likely benign etiology may lead to delayed or inadequate hematuria assessment, subsequently affecting bladder cancer management in some patients. The authors attempted to identify factors that impact on the timeliness and adequacy of hematuria evaluation.
SIU 2017: Predictors of Bladder Cancer Following Hematuria
Lisbon, Portugal (UroToday.com) Bladder cancer typically presents with painless hematuria, although only a minority will have underlying malignancy. The authors aimed to identify predictors of bladder cancer diagnosis following evaluation of hematuria, in order to formulate an appropriate approach to hematuria in Australia.
SIU 2017: En-Bloc Transurethral Resection of Non muscle invasive Bladder Cancer: Pathological Effectiveness
Lisbon, Portugal (UroToday.com) En-bloc transurethral resection (en-bloc TUR) is a modified procedure of transurethral resection of the bladder tumor (TURBT) for the patients with non-muscle invasive bladder cancer. The authors of this study investigated cases of en-bloc TUR and the pathological effectiveness in diagnosis.